CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

From Detecting the Vulnerable Plaque to Managing the Vulnerable Patient 2019 Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD ESC Clinical Practice Guidelines Hypertension: Do Inflammation and Immunity Hold the Key to Solving this Epidemic? Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives Sleep quality and risk of coronary heart disease-a prospective cohort study from the English longitudinal study of ageing Cellular origin and developmental program of coronary angiogenesis Potential Mechanisms of In-stent Neointimal Atherosclerotic Plaque Formation Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular DiseaseA Prespecified Analysis From the FOURIER Trial

GuidelineVolume 73, Issue 24, June 2019

JOURNAL:J Am Coll Cardiol. Article Link

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

SM Grundy, NJ Stone, AL Bailey et al. Keywords: ACC/AHA Clinical Practice Guidelines; biomarkers; coronary artery calcium score; pharmacological; cardiovascular disease; cholesterol; LDL-cholesterol; diabetes mellitus; drug therapy; hydroxymethylglutaryl-CoA reductase inhibitors/statins; hypercholesterolemia; lipids; patient compliance; primary prevention; risk assessment; risk reduction discussion; risk treatment discussion; secondary prevention; ezetimibe; proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9) inhibitors

FULL TEXT PDF